Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today said that the U.S. Food and Drug Administration (FDA) has
requested the submission of new data and analyses from the MODIFY I and
MODIFY II clinical trials previously submitted to the pending Biologics
Licensing Application (BLA) for bezlotoxumab, an investigational agent
for prevention of Clostridium difficile (C. difficile)
infection recurrence.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more